Haas M - Search Results

1

Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Cejka D, Parada-Rodriguez D, Pichler S, Marculescu R, Kramer I, Kneissel M, Gross T, Reisinger A, Pahr D, Monier-Faugere MC, Haas M, Malluche HH. Cejka D, et al. Among authors: haas m. Kidney Int. 2016 Oct;90(4):828-34. doi: 10.1016/j.kint.2016.06.019. Epub 2016 Aug 12. Kidney Int. 2016. PMID: 27528549 Free PMC article.

2

Sclerostin and Dickkopf-1 in renal osteodystrophy.

Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH. Cejka D, et al. Among authors: haas m. Clin J Am Soc Nephrol. 2011 Apr;6(4):877-82. doi: 10.2215/CJN.06550810. Epub 2010 Dec 16. Clin J Am Soc Nephrol. 2011. PMID: 21164019 Free PMC article.

3

Renal elimination of sclerostin increases with declining kidney function.

Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M. Cejka D, et al. Among authors: haas m. J Clin Endocrinol Metab. 2014 Jan;99(1):248-55. doi: 10.1210/jc.2013-2786. Epub 2013 Dec 20. J Clin Endocrinol Metab. 2014. PMID: 24187403

4

Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.

Cejka D, Kodras K, Bader T, Haas M. Cejka D, et al. Among authors: haas m. Kidney Blood Press Res. 2010;33(3):221-6. doi: 10.1159/000316708. Epub 2010 Jun 24. Kidney Blood Press Res. 2010. PMID: 20588059

5

Should teriparatide ever be used for adynamic bone disease?

Cejka D, Haas M. Cejka D, et al. Among authors: haas m. Semin Dial. 2011 Jul-Aug;24(4):431-3. doi: 10.1111/j.1525-139X.2011.00911.x. Semin Dial. 2011. PMID: 21851406 No abstract available.

6

Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease.

Cejka D, Weber M, Diarra D, Reiter T, Kainberger F, Haas M. Cejka D, et al. Among authors: haas m. Bone. 2014 Jul;64:33-8. doi: 10.1016/j.bone.2014.03.048. Epub 2014 Apr 5. Bone. 2014. PMID: 24709688

7

Sclerostin declines during hemodialysis and appears in Dialysate.

Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D. Bielesz BO, et al. Among authors: haas m. Blood Purif. 2014;38(1):30-6. doi: 10.1159/000364992. Epub 2014 Sep 13. Blood Purif. 2014. PMID: 25228355

8

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.

Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M. Cejka D, et al. Among authors: haas m. Nephrol Dial Transplant. 2012 Jan;27(1):226-30. doi: 10.1093/ndt/gfr270. Epub 2011 May 25. Nephrol Dial Transplant. 2012. PMID: 21613383

9

Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.

Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G. Bielesz BO, et al. Among authors: haas m. Clin Biochem. 2014 Sep;47(13-14):1316-9. doi: 10.1016/j.clinbiochem.2014.06.009. Epub 2014 Jun 21. Clin Biochem. 2014. PMID: 24956265

10

Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R. Haas M, et al. Kidney Int. 2003 Mar;63(3):1130-6. doi: 10.1046/j.1523-1755.2003.00816.x. Kidney Int. 2003. PMID: 12631097 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,140 results

Search Page

Filters